High-throughput crystallography to enhance drug discovery

Current Opinion in Chemical Biology

Volumn 7, Issue 3, 2003, Pages 340-345

  Sharff, Andrew ^a   Jhoti, Harren ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN;

ANALYTIC METHOD; CRYSTALLIZATION; CRYSTALLOGRAPHY; GENE SEQUENCE; GENOME ANALYSIS; HIGH THROUGHPUT CRYSTALLOGRAPHY; INTERNET; MOLECULAR BIOLOGY; PROTEIN CRYSTALLOGRAPHY; PROTEIN EXPRESSION; REVIEW; STRUCTURE ANALYSIS; TIME; X RAY CRYSTALLOGRAPHY;

EID: 0038198865     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(03)00062-0     Document Type: Review

References (41)

1. Carr R., Jhoti H. Structure-based screening of low-affinity compounds. Drug Discov Today. 7:2003;522-527.
2. Jhoti H. High-throughput structural proteomics using X-rays. Trends Biotechnol. 19:2001;S67-S71.
3. Kaldor S.W., Kalish V.J., Davies J.F., Shetty B.V., Fritz J.E., Appelt K., Burgess J.A., Campanale K.M., Chirgadze N.Y., Clawson D.K.et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 40:1997;3979-3985.
4. Kim E.E., Baker C.T., Dwyer M.D., Murcko M.A., Rao B.G., Tung R.D., Navia M.A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc. 117:1995;1181-1182.
5. Greer J., Erickson J.W., Baldwin J.J., Varney M.D. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem. 37:1994;1035-1054.
6. Varghese J.N. Development of neuraminidase inhibitors as anti-influenza virus drugs. Drug Dev Res. 46:1999;176-196.
7. Burley S.K. An overview of structural genomics. Nat Struct Biol. 7(suppl):2000;932-934.
8. Terwilliger T.C. Structural genomics in North America. Nat Struct Biol. 7:2000;935-939.
9. Heinemann U. Structural genomics in Europe: slow start, strong finish? Nat Struct Biol. 7:2000;940-942.
10. Yokoyama S., Hirota H., Kigawa T., Yabuki T., Shirouso M., Terada T., Ito Y., Matsuo Y., Kuroda Y., Nishimura Y.et al. Structural genomiucs projects in Japan. Nat Struct Biol. 7:2000;943-945.
11. Burley S.K., Almo S.C., Bonanno J.B., Capel M., Chance M.R., Gaasterland T., Lin D., Sali A., Studier F.W., Swaminathan S. Structural genomics: beyond the human genome project. Nat Genet. 23:1999;151-157.
12. Heinemann U., Illing G., Oschkinat H. High-throughput three-dimensional protein structure determination. Curr Opin Biotechnol. 12:2001;348-354.
13. Blundell T.L., Jhoti H., Abell C. High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Disc. 1:2002;45-54 A comprehensive review of how advances in process automation and informatics have facilitated the development of high-throughput X-ray crystallography.
14. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A., Holt R.A.et al. The sequence of the human genome. Science. 291:2001;1304-1351.
15. Campbell S.F. Science, art and drug discovery: a personal perspective. Clin Sci. 99:2000;255-260.
16. Norvell J.C., Machalek A.Z. Structural genomics programs at the US National Institute of General Medical Sciences. Nat Struct Biol. 7:2000;931.
17. Dry S., McCarthy S., Harris T. Structural genomics in the biotechnology sector. Nat Struct Biol. 7:2000;946-949.
18. Stevens R. Design of high-throughput methods of protein production for structural biology. Structure. 8:2000;177-185.
19. Lesley S.A. High throughput proteomics: protein expression and purification in the post-genomic world. Protein Exp Purif. 22:2001;159-164.
20. Lesley S.A., Kuhn P., Godzik A., Deacon A.M., Mathews I., Kreusch A., Spraggon G., Klock H.E., McMullan D., Shin T.et al. Structural genomics of the Thermotoga maritime proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci USA. 99:2002;11664-11669.
21. Service R.F. Structural genomics. Tapping DNA for structures produces a trickle. Science. 298:2002;948-950.
22. Chayen N.E., Shaw Stewart P., Baldock P. New developments of the IMPAX small volume automated crystallisation system. Acta Crystallogr. D50:1994;456-458.
23. de Titta G: Gearing up for ∼40K crystallisation experiments a day: meeting the needs of HT structural proteomics projects. 8th International Conference on the Crystallisation of Biological Macromolecules (ICCBM8) 2000, http://iccbm8.cmc.uab.edu/Abstracts/Luft-1.html .
24. Goodwill K.E., Tennant M.G., Stevens R.C. High-throughput X-ray crystallography for structure-based drug design. Drug Discov Today. 6:2001;S113-S118.
25. Kuhn P., Wilson K., Patch M.G., Stevens R.C. The genesis of high-throughput structure-based drug discovery using protein crystallography. Curr Opin Chem Biol. 6:2002;704-710 Advances in sub-microliter, automated protein crystallisation systems and automatic crystal visualisation systems have enabled direct integration into the drug-discovery process and led to significant increases in throughput.
26. Stevens R.C. High-throughput crystallisation. Curr Opin Struct Biol. 10:2000;558-563 A review of efforts at automation and miniaturisation of protein crystallisation.
27. Rose D. Microdispensing technologies in drug discovery. Drug Discov Today. 4:1999;411-419.
28. Hansen C.L., Skordalakes E., Berger J.M., Quake S.R. A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion. Proc Natl Acad Sci USA. 99:2002;16531-16536.
29. Bodenstaff E.R., Hoedemaeker F.J., Kuil M.E., De Vrind H.P., Abrahams J.P. The prospects of protein nanocrystallography. Acta Crystallogr. D58:2002;1901-1906.
30. Wilson J. Towards the automated evaluation of crystallisation trials. Acta Crystallogr. D58:2002;1907-1914.
31. Watanabe N. Semi-automatic protein crystallisation system that allows in situ observation of X-ray diffraction from crystals in the drop. Acta Crystallogr. D58:2002;1527-1530.
32. Muchmore S.W., Olson J., Jones R., Pan J., Blum M., Greer J., Merrick S.M., Magdalinos P., Nienaber N.L. Automated crystal mounting and data collection in protein crystallography. Structure. 58:2000;243-246 Development and use of an in-house automated crystal sample changer.
33. Sharff AJ: High Throughput Crystallography on an in-house source, using ACTOR. Rigaku Journal 2003, in press.
34. Terwilliger T.C., Berendzen J. Automated MAD and MIR structure solution. Acta Crystallogr. D55:1999;849-861.
35. Terwilliger T.M. Maximum-likelihood density modification. Acta Crystallogr. D56:2000;965-972.
36. Morris R.J., Perrakis A., Lamzin V.S. ARP/wARP's model-building algorithms. I. The main chain. Acta Crystallogr. D58:2002;968-975.
37. Blundell TL, Abell C, Cleasby A, Hartshorn MJ, Tickle IJ, Parasini E, Jhoti H: High-throughput X-ray crystallography for drug discovery. Drug Design: Special Publication. Edited by Flower DR. Cambridge: Royal Society of Chemistry; 2002, 279:53-59.
38. Verlinde CLMJ, Kim H, Bernstein BE, Mande SC, Hol WGJ: Antitrypanosomiasis drug development based on structures of glycolytic enzymes. In Structure-based Drug Design. Edited by Veerapandian P. New York: Marcel Dekker Inc; 1997:365-394.
39. Nienaber V.L., Richardson P.L., Klighofer V., Bouska J.J., Giranda V.L., Greer J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotech. 18:2000;1105-1108 How to use fragment based approach to high-throughput X-ray crystallographic screening.
40. Lesuisse D., Lange G., Deprez P., Benard D., Schoot B., Delettre G., Marquette J.P., Broto P., Jean-Baptiste V., Bichet P.et al. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J Med Chem. 45:2002;2379-2387.
41. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimated solubility and permeability in drug discovery and development. Adv Drug Delivery Res. 46:2001;3-26.